Cerus Corporation

Cerus is headquartered in the United States and derives a large share of its commercial opportunity from the U.S. market, where it is still working to broaden adoption of INTERCEPT for platelets, plasma, and red blood cells. The company also operates through Cerus Europe B.V. in the Netherlands, reflecting a meaningful European operating footprint and regulatory presence. Management notes that gross margin is affected by geographic mix, with higher U.S. kit sales improving margins relative to other regions, while foreign exchange and import tariffs can pressure profitability. China is a strategic expansion market through a 51%-owned joint venture, but commercialization there depends on regulatory approval, clinical studies, and cybersecurity compliance. Because many territories are served through distributors, geography affects not only sales concentration but also customer access, payment timing, and regulatory execution.

Cerus is highly dependent on the commercial success of INTERCEPT in the U.S., so slower-than-expected adoption would directly limit growth and profitability. The company also faces execution risk in distributor-led markets, where partner transitions can disrupt customer relationships, delay collections, and reduce revenue if replacement channels underperform. Regulatory risk is material because product approvals, CE certificates, post-approval studies, and local compliance requirements can delay launches or force additional spending. China adds a distinct risk layer because the JV must obtain regulatory approval and meet cybersecurity requirements before commercialization can begin. More generally, as a medical device and blood-safety company, Cerus is exposed to supply chain disruption, foreign exchange, tariffs, and healthcare reimbursement or policy changes that can affect demand and margins.